KR920021492A - 4-[2-(2-히드록시-2-페닐에틸아미노)에톡시]페닐 아세트산 및 그것의 생물학적 전구체 화합물 - Google Patents

4-[2-(2-히드록시-2-페닐에틸아미노)에톡시]페닐 아세트산 및 그것의 생물학적 전구체 화합물 Download PDF

Info

Publication number
KR920021492A
KR920021492A KR1019920008405A KR920008405A KR920021492A KR 920021492 A KR920021492 A KR 920021492A KR 1019920008405 A KR1019920008405 A KR 1019920008405A KR 920008405 A KR920008405 A KR 920008405A KR 920021492 A KR920021492 A KR 920021492A
Authority
KR
South Korea
Prior art keywords
compound
formula
ethoxy
hydroxy
pharmaceutically acceptable
Prior art date
Application number
KR1019920008405A
Other languages
English (en)
Inventor
브라이언 로이 할로웨이
랄프 호위
발비어 싱그 라오
Original Assignee
수잔 제인 젠틀
임페리얼 케미칼 인더스트리스 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 수잔 제인 젠틀, 임페리얼 케미칼 인더스트리스 피엘씨 filed Critical 수잔 제인 젠틀
Publication of KR920021492A publication Critical patent/KR920021492A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/04—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/06—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • C07C251/08—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton being acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/04—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/10—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C07C251/16—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Detergent Compositions (AREA)

Abstract

내용 없음

Description

4-[2-(2-히드록시-2-페닐에틸아미노]에톡시]페닐 아세트산 및 그것의 생물학적 전구체 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 하기 구조식(Ⅰ)의 화합물 또는 그것의 생물학적 전구체 또는 그것의 약학적 허용염:
  2. 제1항에 있어서, 상기 화합물의 카르복실산 형태이거나 그것의 약학적 허용염인 것을 특징으로 하는 화합물.
  3. 제2항에 있어서, 상기 화합물이 염산염으로 형성된 염 형태인 것을 특징으로 하는 화합물.
  4. 제1항에 있어서, 하기 구조식(Ⅱ)의 화합물 또는 그것의 약학적 허용염인 것을 특징으로 하는 화합물:
    상기식에서 R4는 C1-6알콕시이다.
  5. 제4항에 있어서, R4가 메톡시인 것을 특징으로 하는 화합물.
  6. 제1항에있어서, (R)-4-[2-(2-히드록시-2-페닐에틸아미노)에톡시]페닐아세트산, (R)-4-[2-(2-히드록시-2-페닐에틸아미노)에톡시]페닐아세트아미드, (R)-메틸-4-[2-(2-히드록시-2-페닐에틸아미노)에톡시]페닐아세테이트, 4-[2-(2-히드록시-2-페닐에틸아미노)에톡시]페닐아세트산, 4-[2-(2-히드록시-2-페닐에틸아미노)에톡시]페닐 아세트 아미드, 또는 메틸 4-[2-(2-히드록시-2-페닐에틸아미노)에톡시]페닐 아세테이트나 그것의 약학적 허용염인 것을 특징으로 하는 화합물.
  7. 제1항의 화합물 또는 그것의 생물학적 전구체 또는 그것의 약학적 허용염 및 약학적 허용 담체를 포함하는 약학적 조성물.
  8. 제1항의 화합물을 제조하기 위한 방법으로서, (a) 하기 구조식(Ⅲ) 또는 (Ⅳ)의 화합물과 하기 구조식(Ⅴ)의 화합물을 반응시키거나, (b) 하기 구조식(Ⅵ)의 화합물을 가수분해 하거나, (c) 4-[2-(2-히드록시-2-페닐에틸아미노)에톡시]페닐 아세트산의 경우 하기 구조식(Ⅶ)의 화합물을 가수분해하거나, (d) 하기 구조식(Ⅷ)의 화합물을 하기 구조식(IX)의 화합물과 반응시키거나, (e) 하기 구조식(X)의 화합물의 보호기를 제거하거나, (f) 4-[2-(2-히드록시-2-페닐 에틸 아미노)에톡시]페닐 아세트산을 생물학적 전구체로 전환시키거나, 역으로, 4-[2-(2-히드록시-2-페닐 에틸 아미노)에톡시]페닐 아세트산의 생물학적 전구체를 4-[2-(2-히드록시-2-페닐 에틸 아미노)에톡시]페닐 아세트산의 또다른 생물학적 전구체로 전환시키거나, (g) 하기 구조식(XI)의 화합물을 환원시키거나, (h) 하기 구조식(XII)의 화합물을 환원시키거나, (i) 하기 구조식(XIII)의 화합물을 환원시키며, 여기에서 임의의 작용기를 선택적으로 보호하고 그후 필요하다면 (ⅰ) 임의의 작용기를 제거하고, (ⅱ) 약학적 허용염을 형성하는 것을 포함하는 방법:
    상기식에서,-COR4는 카르복시 또는 그겻의 생물학적 전구체이며, L와 L'은 이탈기이고, R5는 가수분해성기이며, R6는 -COR4기의 보호된 유도체이다.
  9. 제8항에서 규정 구조식(Ⅵ), (Ⅹ), (XI), (XII) 또는 (XIII)의 화합물.
  10. 하기 구조식의 화합물;
  11. 제1항의 화합물 또는 그것의 생물학적 전구체 또는 그것의 약학적 허용염을 β3-아드레날린성 수용체를 통해 매개되는 질병을 치료하기 위해 사용하는 방법.
  12. 제1항의 화합물 또는 그것의 생물학적 전구체 또는 그것의 약학적 허용염을 발열촉진 및/또는 글루코오즈 내성을 향상시키는데 사용하는 방법.
  13. 제1항의 화합물 또는 그것의 생물학적 전구체 또는 그것의 약학적 허용염을 비만증, 성숙기 개시 당뇨병, NIDDM, 고혈압 및/또는 과유지질혈증을 치료하는데 사용하는 방법.
  14. 제1항의 화합물 또는 그것의 생물학적 전구체 또는 그것의 약학적 허용염을 과트리글리세라이드 혈증, 콜레스테롤과잉 혈증, 아테롬성 동맥경화증 및 HDL 저레벨증을 치료하는데 사용하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920008405A 1991-05-28 1992-05-19 4-[2-(2-히드록시-2-페닐에틸아미노)에톡시]페닐 아세트산 및 그것의 생물학적 전구체 화합물 KR920021492A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919111426A GB9111426D0 (en) 1991-05-28 1991-05-28 Chemical compounds
GB9111426.4 1991-05-28

Publications (1)

Publication Number Publication Date
KR920021492A true KR920021492A (ko) 1992-12-18

Family

ID=10695679

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920008405A KR920021492A (ko) 1991-05-28 1992-05-19 4-[2-(2-히드록시-2-페닐에틸아미노)에톡시]페닐 아세트산 및 그것의 생물학적 전구체 화합물

Country Status (32)

Country Link
US (3) US5393779A (ko)
EP (1) EP0516349B1 (ko)
JP (1) JP3232337B2 (ko)
KR (1) KR920021492A (ko)
CN (1) CN1031564C (ko)
AP (1) AP301A (ko)
AT (1) ATE128115T1 (ko)
AU (1) AU652826B2 (ko)
BG (1) BG96392A (ko)
BR (1) BR9202002A (ko)
CA (1) CA2068377A1 (ko)
CS (1) CS159292A3 (ko)
DE (1) DE69204906T2 (ko)
DK (1) DK0516349T3 (ko)
ES (1) ES2076688T3 (ko)
FI (1) FI922424A (ko)
GB (2) GB9111426D0 (ko)
GR (1) GR3017462T3 (ko)
HU (2) HU211401B (ko)
IE (1) IE69043B1 (ko)
IL (1) IL101821A0 (ko)
MY (1) MY136249A (ko)
NO (1) NO922113L (ko)
NZ (1) NZ242643A (ko)
OA (1) OA10077A (ko)
PL (1) PL294704A1 (ko)
RO (1) RO111569B1 (ko)
RU (1) RU2073666C1 (ko)
SI (1) SI9200093A (ko)
TW (1) TW198709B (ko)
YU (1) YU54592A (ko)
ZA (1) ZA923356B (ko)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
US6696486B1 (en) * 1992-01-22 2004-02-24 Glaxo Group Limited Medical use for atypical β-adrenoceptor agonists
ATE215365T1 (de) * 1992-01-22 2002-04-15 Glaxo Group Ltd Medizinische verwendung von atypischen beta- adrenoceptor agonisten
GB9207964D0 (en) * 1992-04-10 1992-05-27 Ici Plc Chemical compounds
GB9209076D0 (en) * 1992-04-27 1992-06-10 Ici Plc Chemical compounds
US5662934A (en) * 1993-01-05 1997-09-02 Najarian; Thomas Compositions and methods for lowering cholesterol while maintaining antioxidant levels
GB9313574D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Medicaments
US5482971A (en) * 1993-10-01 1996-01-09 American Cyanamid Company Beta3 -adrenergic agents and their use in pharmaceutical compositions
US5563171A (en) * 1993-11-05 1996-10-08 American Cyanamid Company Treatment of glaucoma and ocular hypertension with β3-adrenergic agonists
US5578638A (en) * 1993-11-05 1996-11-26 American Cyanamid Company Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
US5541197A (en) * 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5627200A (en) * 1994-09-26 1997-05-06 Pfizer Inc β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia
US6090836A (en) * 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
US6020382A (en) * 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
ID27415A (id) 1998-06-30 2001-04-05 Takeda Chemical Industries Ltd Komposisi farmaseutik
CA2398199A1 (en) * 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha Novel therapeutic agents that use a .beta.3 agonist
US6987131B1 (en) 2000-06-26 2006-01-17 Burzynski Stanislaw R Phenylacetic acid compositions for treating or preventing hypercholesterolemia
CA2495537C (en) 2000-08-29 2010-03-30 Nobex Corporation Immunoregulatory compounds and derivatives and methods of treating diseases therewith
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
US7709677B2 (en) 2001-01-31 2010-05-04 Glaxosmithkline Llc Process of preparing arylethanoldiamines
JP2004331500A (ja) * 2001-02-16 2004-11-25 Dainippon Pharmaceut Co Ltd 血中濃度制御製剤
EP1236723A1 (en) 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
AU2003209527A1 (en) 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
EP1478625A1 (en) * 2002-02-27 2004-11-24 Pfizer Products Inc. Processes and intermediates useful in preparing beta-3-adrenergic receptor agonists
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
CN102633637A (zh) * 2012-03-30 2012-08-15 吉林大学 有效缓解和治疗便秘的药用配方
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US11766419B2 (en) * 2021-01-08 2023-09-26 Banasthali Vidyapith Mebeverine as soluble epoxide hydrolase inhibitor
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1245148A (en) * 1968-11-18 1971-09-08 Pfizer Ltd Propanolamine derivatives
GB1301134A (en) * 1970-07-18 1972-12-29 Pfizer Ltd SUBSTITUTED 1-PHENYL-2-ALLYLAMINO-ALKANOLS, 1-PHENYL-2-ALLYLAMINO-ALKANES AND alpha-AMINOALKYLPHENYL KETONES
EP0006735B1 (en) * 1978-06-28 1983-06-15 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
DE3061205D1 (en) * 1979-06-16 1983-01-05 Beecham Group Plc Secondary amines, their preparation and use in pharmaceutical compositions
US4338333A (en) * 1979-06-16 1982-07-06 Beecham Group Limited Ethanamine derivatives their preparation and use in pharmaceutical compositions
DE3062216D1 (en) * 1979-09-06 1983-04-07 Beecham Group Plc Cinnamic acid derivatives, their preparation, and pharmaceutical compositions containing them
DE3061693D1 (en) * 1979-10-25 1983-02-24 Beecham Group Plc Secondary amines, their preparation and use in pharmaceutical compositions
EP0040000B1 (en) * 1980-05-08 1983-10-12 Beecham Group Plc Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions
DE3260490D1 (en) * 1981-03-31 1984-09-06 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
EP0063004A1 (en) * 1981-04-09 1982-10-20 Beecham Group Plc Secondary amines, processes for their preparation, and pharmaceutical compositions containing them
GB8519154D0 (en) * 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
IT1204416B (it) * 1986-06-27 1989-03-01 Midy Spa Medicamenti a base di analoghi di feniletanolammine per il trattamento di disturbi gastro-intestinali ed uterini
GB8714901D0 (en) * 1986-07-23 1987-07-29 Ici Plc Amide derivatives
GB2212801A (en) * 1987-11-26 1989-08-02 Resolution Chemicals Limited Preparation of an alkanolamine derivatives
GB8801306D0 (en) * 1988-01-21 1988-02-17 Ici Plc Chemical compounds
GB8910374D0 (en) * 1989-05-05 1989-06-21 Ici Plc Chemical compounds
DE69028877T2 (de) * 1989-06-13 1997-02-27 Sanofi Sa Verwendung von Phenylethanolaminen zur Herstellung von Medikamenten gegen Augenleiden

Also Published As

Publication number Publication date
HU210799A9 (en) 1995-07-28
FI922424A (fi) 1992-11-29
JP3232337B2 (ja) 2001-11-26
RO111569B1 (ro) 1996-11-29
DE69204906T2 (de) 1996-02-08
AP9200385A0 (en) 1992-07-31
JPH05148196A (ja) 1993-06-15
YU54592A (sh) 1995-10-03
CA2068377A1 (en) 1992-11-29
CS159292A3 (en) 1992-12-16
DE69204906D1 (de) 1995-10-26
EP0516349B1 (en) 1995-09-20
CN1031564C (zh) 1996-04-17
HU211401B (en) 1995-11-28
AU652826B2 (en) 1994-09-08
TW198709B (ko) 1993-01-21
NO922113D0 (no) 1992-05-27
HU9201609D0 (en) 1992-08-28
OA10077A (en) 1996-12-18
US5434184A (en) 1995-07-18
HUT62256A (en) 1993-04-28
ZA923356B (en) 1993-03-05
BR9202002A (pt) 1993-01-12
EP0516349A2 (en) 1992-12-02
NZ242643A (en) 1994-12-22
AU1704492A (en) 1992-12-03
DK0516349T3 (da) 1995-11-06
PL294704A1 (en) 1993-07-26
NO922113L (no) 1992-11-30
CN1069023A (zh) 1993-02-17
IE921447A1 (en) 1992-12-02
RU2073666C1 (ru) 1997-02-20
GB9111426D0 (en) 1991-07-17
EP0516349A3 (en) 1993-04-14
US5393779A (en) 1995-02-28
AP301A (en) 1994-01-21
FI922424A0 (fi) 1992-05-27
BG96392A (bg) 1993-12-24
GB9210919D0 (en) 1992-07-08
ES2076688T3 (es) 1995-11-01
MY136249A (en) 2008-08-29
ATE128115T1 (de) 1995-10-15
GR3017462T3 (en) 1995-12-31
IL101821A0 (en) 1992-12-30
US5480910A (en) 1996-01-02
IE69043B1 (en) 1996-08-07
SI9200093A (en) 1992-12-31

Similar Documents

Publication Publication Date Title
KR920021492A (ko) 4-[2-(2-히드록시-2-페닐에틸아미노)에톡시]페닐 아세트산 및 그것의 생물학적 전구체 화합물
KR950702982A (ko) 치환된 티아졸리딘디온 유도체(Substituted Thiazolidinedione Derivatives)
FI96857B (fi) Menetelmä valmistaa farmakologisesti käyttökelpoista tiatsoliyhdistettä
KR930701415A (ko) 약학적으로 활성인 벤조퀴나졸린 화합물
KR930019667A (ko) 항-종양 화합물
US4391825A (en) N-[[6-(Lower alkoxy)-5-(trifluoromethylthio)-1-naphthalenyl]thioxomethyl]-N-(lower alkyl)glycines
KR950014064A (ko) 시클릭 아미노산 유도체
AU642368B2 (en) Resolution of furopyridine enantiomers and synthetic precursors thereof
CA1182472A (en) N-[(2-naphthalenyl)thioxomethyl]glycine derivatives
KR880011154A (ko) 벤즈옥사진 유도체 및 이의 제조방법
KR940009177A (ko) 항레트로바이러스성 아실 화합물
IL122664A0 (en) Esters and amides as PLA2 inhibitors
KR830007683A (ko) 7β-[2-(2-아미노-4-티아졸릴)-2-(신)-메톡시 아미노 아세트 아미도]-3-세펨-4-카복실산의 에스테르의 제조방법
KR920018036A (ko) 티아졸리디논 및 옥사졸리디논 유도체, 그의 제조방법 및 혈관확장제로서의 용도
KR950701905A (ko) 치환된 (아릴알킬아미노벤질)아미노프로피온아미드 유도체, 이의 제조방법 및 간질치료제, 신경보호제 및 우울증치료제로서의 이의 용도(Substituted (arylalkyla-minobenzyl)aminopropionamide derivatives, their preparation and use anti-epileptic, neuroprotective and antidepressant agents)
KR840004757A (ko) 세파로스포린 유도체의 제조방법
KR880003930A (ko) 설폰아미도에틸 화합물, 이들 화합물을 함유하는 약제학적 조성물 및 그들의 제조방법
KR850002988A (ko) 페니실린 유도체의 제조방법
KR920701123A (ko) 2-히드록시-3-페녹시프로필아미노화합물 및 그 유도체
NO178025C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive (benzhydryloksyetylpiperidyl)alifatiske syrederivater
FR2566405B1 (fr) Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2 par une fonction aminee, leur preparation, leur application comme medicaments, les compositions les renfermant et les intermediaires nouveaux obtenus
KR890013048A (ko) 이미다졸 유도체, 그 제법 및 그의 사용
KR890003779A (ko) β-락탐 화합물, 이 화합물의 제조방법, 이 화합물의 합성용 중간체 및 이 화합물을 함유하는 세균감염 질환 치료용 의약조성물
KR920701144A (ko) 아미노산 유도체
AU585703B2 (en) Process for the enzymatic resolution of racemic 2-amino- 1-alkanols

Legal Events

Date Code Title Description
N231 Notification of change of applicant
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid